NEW YORK (GenomeWeb News) – Phenomenome Discoveries has granted Polymedco Cancer Diagnostic Products a license to commercialize Phenomenome's mass spectrometry-based blood test for colorectal cancer in the US.

The test uses triple quadrupole mass spec technology to detect a deficiency in novel anti-cancer and anti-inflammatory metabolites in a blood sample, which Phenomenome said it has discovered occurs in nine out of 10 patients with colorectal cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.